Back to Authors

Tariq, Wajeeha

https://orcid.org/0000-0001-8387-4309

Mayo Clinic

Mayo Clinic

Citations 4

Escalating incidence of infective endocarditis in Europe in the 21st century
Talha, Khawaja M. , Thornhill, Martin H. , Arshad, Verda , Tariq, Wajeeha , Tleyjeh, Imad M, Scott, Christopher G. , Hyun, Meredith C, Bailey, Kent R. , Anavekar, Nandan S., Palraj, Raj , Tleyjeh, Imad M. , Scott, Christopher , Thornhill, M H , Tleyjeh, Imad M , Palraj, Raj , Baddour, Larry M. , Hyun, Meredith C, Sohail, M. Rizwan , DeSimone, Daniel C. , Dayer, Mark

Open Heart | October 20, 2021 | Volume: 8 | Issue: 2 | Pages: e001846

10.1136/openhrt-2021-001846 Get It

Aim To provide a contemporary analysis of incidence trends of infective endocarditis (IE) with its changing epidemiology over the past two decades in Europe. Methods A systematic review was conducted at the Mayo Clinic, Rochester. Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus and Web of Science were searched for studies published between 1 January 2000 and 30 November 2020. All studies were independently reviewed by four referees and those that included a population-based incidence of IE in patients, irrespective of age, in Europe were included. Least squares regression was used to estimate pooled temporal trends in IE incidence. Results Of 9138 articles screened, 18 studies were included in the review. Elderly men predominated in all studies. IE incidence increased 4.1% per year (95% CI 1.8% to 6.4%) in the pooled regression analysis of eight studies that included comprehensive and consistent trends data. When trends data were weighted according to population size of individual countries, an increase in yearly incidence of 0.27 cases per 100 000 people was observed. Staphylococci and streptococci were the most common pathogens identified. The rate of surgical intervention ranged from 10.2% to 60.0%, and the rate of inpatient mortality ranged from 14.3% to 17.5%. In six studies that examined the rate of injection drug use, five of them reported a rate of less than 10%. Conclusion Based on findings from our systematic review, IE incidence in Europe has doubled over the past two decades in Europe. Multiple factors are likely responsible for this striking increase. Trial registeration number CRD42020191196.
Temporal Trends of Infective Endocarditis in North America From 2000 to 2017—A Systematic Review
Talha, Khawaja M. , Thornhill, Martin H. , Tariq, Wajeeha , Arshad, Verda , Tleyjeh, Imad M, Bailey, Kent R. , Palraj, Raj , Anavekar, Nandan S., Tleyjeh, Imad M. , DeSimone, Daniel C , Thornhill, M H , Tleyjeh, Imad M , Palraj, Raj , Dayer, Mark , Sohail, M. Rizwan , DeSimone, Daniel C. , Baddour, Larry M.

Open Forum Infectious Diseases | September 25, 2021 | Volume: 8 | Issue: 11 | Pages: No page available

10.1093/ofid/ofab479 Get It

Abstract Background The objective of this paper was to examine temporal changes of infective endocarditis (IE) incidence and epidemiology in North America. Methods A systematic review was conducted at Mayo Clinic, Rochester. Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science were searched for studies published between January 1, 2000, and May 31, 2020. Four referees independently reviewed all studies, and those that reported a population-based incidence of IE in patients aged 18 years and older in North America were included. Results Of 8588 articles screened, 14 were included. Overall, IE incidence remained largely unchanged throughout the study period, except for 2 studies that demonstrated a rise in incidence after 2014. Five studies reported temporal trends of injection drug use (IDU) prevalence among IE patients with a notable increase in prevalence observed. Staphylococcus aureus was the most common pathogen in 7 of 9 studies that included microbiologic findings. In-patient mortality ranged from 3.7% to 14.4%, while the percentage of patients who underwent surgery ranged from 6.4% to 16.0%. Conclusions The overall incidence of IE has remained stable among the 14 population-based investigations in North America identified in our systematic review. Standardization of study design for future population-based investigations has been highlighted for use in subsequent systematic reviews of IE.
Impact of delayed device re‐implantation on outcomes of patients with cardiovascular implantable electronic device related infective endocarditis
Arshad, Verda , Lahr, Brian D. , Khalil, Sarwat , Tariq, Wajeeha , Talha, Khawaja M. , Cha, Yong‐Mei , DeSimone, Daniel C. , Talha, Khawaja Muhammad, Cha, Yong-Mei , DeSimone, Daniel C , Baddour, Larry M. , Sohail, M. Rizwan

Pacing and Clinical Electrophysiology | June 16, 2021 | Volume: 44 | Issue: 8 | Pages: 1303-1311

10.1111/pace.14297 Get It

AbstractBackgroundOptimal timing of cardiovascular implantable electronic device (CIED) re‐implantation following device removal due to infection is undefined. Multinational guidelines reflect this and include no specific recommendation for this timing, while others have recommended waiting at least 14 days in cases of CIED related infective endocarditis (CIED‐IE). The current work seeks to clarify this issue.MethodsWe retrospectively reviewed institutional data at Mayo Clinic, Minnesota of patients aged ≥ 18 years who developed CIED‐IE from January 1, 1991 to February 1, 2016. CIED‐IE was defined as echocardiogram reported device lead or valvular vegetation. Regression analyses were used to relate the risk of clinical outcomes to the interval between CIED removal and re‐implantation and the location of vegetations.ResultsA total of 109 patients met study inclusion criteria. A majority (68.8%) of patients were men and the median age was 68.0 years. Transoesophageal echocardiogram (TEE) was performed in 95.4% of patients, with valve vegetations detected in 33.9% (n = 37). Survival analysis comparing patients in whom device re‐implantation was < 14 days vs. ≥14 days, and further categorized by those with and without valve vegetation, showed a significant difference (P = 0.028); patients with valve vegetation and reimplantation interval < 14 days had the lowest (58.7%) 12‐month survival. When adjusted for valve vegetation, longer time interval for reimplantation trended toward increased hospital length of stay (P = 0.079).ConclusionOur findings suggest that the recommended 14‐day delay between CIED extraction and re‐implantation in CIED‐IE patients is associated with a survival benefit, but longer length of hospital stay following re‐implantation.
Abstract 15979: Utility of Post-extraction Follow-up Blood Cultures in Patients With Cardiovascular Implantable Electronic Device Infection
Khalil, Sarwat , Garrigos, Zerelda Esquer , Gurram, Pooja , Tariq, Wajeeha , CastilloAlmeida, Natalia, Wilson, Walter R. , Lahr, Brian D. , Challener, Douglas W. , Baddour, Larry M. , DeSimone, Daniel C. , Sohail, M. Rizwan

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.15979 Get It

Introduction: Cardiovascular implantable electronic devices (CIED) infections are frequently complicated with bloodstream infection (BSI). Complete device removal and prolonged antimicrobial therapy is essential for cure. The frequency of persistent BSI after source control (device extraction) is not well described. This study aims to assess the utility of repeat blood cultures (BC) after device extraction as recommended by the American Heart Association (AHA) guidelines. Methods: We selected patients who presented with BSI in the setting of CIED infection and underwent device removal at Mayo Clinic Rochester between 2012 and 2017. Cases where BC were not drawn prior to extraction, or repeated within 72 hours of device extraction, or met criteria for contamination were excluded. Results: Of 656 patients who underwent CIED extraction for device infection, 190 with post-extraction BC met study criteria. Among the final study cohort (Table 1), 159 patients had negative BC, while 31 had positive BC following CIED extraction. Pre-extraction, the most common causative organism was Staphylococcus aureus (91/190, 48%) (Figure 1a). Post-extraction, 22 of the 31 (71%) cases of persistent BSI were due to S. aureus (Fig 1b). The median duration of BSI was not significantly different between negative and positive BC groups (3 versus 4 days, p=0.92). Conclusions: Majority of patients had resolution of BSI after CIED extraction. S. aureus was the most common cause of persistent BSI post-extraction. Our findings support the AHA guidelines of repeating BC after device extraction, especially for S aureus .